The US Rosacea Market: Size, Trends & Forecasts (20018-2022)
Scope of the Report
The report titled “The US Rosacea Market: Size, Trends & Forecasts (20018-2022)”, provides a detailed analysis of the US rosacea market with market sizing and growth pattern. The analysis includes rosacea market in terms of value, number of patients; number of patients seeking treatment and market share by segments. It also provides analysis of the US dermatology drugs market in terms of value and market share by segments.
Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the US rosacea market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Foamix Pharmaceuticals Ltd., Bayer Group, Galderma and Valeant Pharmaceuticals International are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.
Foamix Pharmaceuticals Ltd.
Valeant Pharmaceuticals International
Rosacea is a common chronic condition of the skin with a high prevalence rate among the US population. It is observed that it naturally begins at any time after the age of 30 and more and mostly affect the area of nose, cheeks and forehead. In some cases, rosacea may also occur on the neck, chest, scalp or ears. Rosacea symptoms and signs include facial flushing, fine red vascular lines, swollen, red eyelids and many more. The disease is more common in women and those who have fair skin. The cause of such skin condition is still unknown and cannot be cured. The only way to control rosacea is by minimizing its symptoms.
The US rosacea market has grown over the past few years and is anticipated to grow during the forecasted period also i.e. 2018-2022 at a high growth rate on the back of rising incidence rate of the disease among the US population.
The growth in the market will be driven by aging population, unhealthy eating habits and environmental factors, rising disposable income and entry of new drugs and treatments in the market. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.